



## Company Announcement

### Nykode Therapeutics to host Capital Markets Day

- Nykode Therapeutics will host a Capital Markets Day on May 12, 2022 from 2 p.m. CET
- Topics to be discussed will include a comprehensive business update, including the Company's plans for an uplift to the main market of Oslo Stock Exchange (Oslo Børs) and insights into Nykode's technology platform

Oslo, Norway, April 19, 2022 – Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that it will host a Capital Markets Day for investors and analysts on May 12, 2022 from 2 p.m. CET / 8 a.m. ET. The event will be hosted both with the possibility for physical attendance at Nykode's facilities in Oslo, Norway, as well as a live webcast. The Capital Markets Day will feature updates on Nykode's business, innovations and latest developments.

Further details of the agenda and registration details will follow.

#### **Nykode Therapeutics**

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.

The Company's partnerships include Roche and Genentech within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.



Nykode Therapeutics' shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is NYKD. Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.

**Contact for Nykode Therapeutics AS:**

CEO Michael Engsig  
Nykode Therapeutics AS  
[IR@nykode.com](mailto:IR@nykode.com)

**Nykode Therapeutics AS**

Oslo Science Park  
Gaustadalléen 21  
N-0349 Oslo, Norway

**Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.